Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
EjaculationAssessment of efficacy and safety UK-390,957
TPTNS for Treating Patients With Premature Ejaculation
Premature EjaculationBackground: Transcutaneous posterior tibial nerve stimulation is an effective therapy for controlling urinary incontinence. Premature ejaculation (PE) and urinary incontinence are anatomically and physio-pathologically similar. Based on this, the use of this therapy is considered to be viable for the control of PE. Objective: To evaluate the efficacy of transcutaneous posterior tibial nerve electrostimulation for the ejaculatory reflex. Patients and Methods: Phase II clinical trial. Patients with a diagnosis of premature ejaculation who are treated at the Colombia Boston Medical Group clinic will be included. The participants will receive 3 transcutaneous posterior tibial nerve stimulation therapies per week for 12 weeks. The IELT and the PEDT scale will be evaluated on week 6, at the end of treatment and three months after completing the protocol.
The Effect of Behavioral Therapy Given to Men and Their Partners'
Premature EjaculationSexual Function DisturbancesPremature ejaculation involves not only sexual problems but also relationship and communication difficulties, and behavioral approaches to the treatment of premature ejaculation are promising.
Trial of PED-1 in Male Patients With Premature Ejaculation
Premature EjaculationThe purpose of this study is to evaluate whether PED-1 is more effective than Placebo in the treatment of premature ejaculation.
IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men...
Premature EjaculationThe purpose of this study is to determine the effectiveness of IX-01 in men with lifelong premature ejaculation.
A Safety and Tolerability Study of Administration of PSD502
Premature EjaculationA Phase I, Single-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Pharmacokinetic and Safety Study to Evaluate Systemic Exposure and Local Vaginal Exposure to Lidocaine and Prilocaine and the Metabolites 2,6 DiMethylAlanine (2, 6, DMA) and O-Toluidine; and the Safety and Tolerability of PSD502 in Female Healthy Volunteer Subjects Following Daily Application to the Vagina and Cervix for Seven Days With Three Different Doses of PSD502 or Placebo
A Study On Concentrations Of 16448 In Blood And The Safety Of This Compound In Healthy Males With...
Premature Ejaculation16448 is being investigated for the treatment of primary premature ejaculation (PE) using a novel mode of action. There are no approved therapies for premature ejaculation, and novel therapies are needed for this syndrome. 16448 has been shown to increase ejaculatory latency in the PCA rat model of premature ejaculation. A novel instrument, the Sexual Assessment Monitor (SAM), will be used to measure ejaculatory latency time in this study. This device, which measures ELT under standard conditions, has been shown to provide a more reliable measure of ejaculatory latency compared to the use of a stopwatch during sexual intercourse
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation...
Erectile DysfunctionThe primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).
A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation
Sexual DysfunctionEjaculationThe primary purpose of the study is to assess the possible withdrawal effects after abruptly stopping daily therapy with dapoxetine compared with continuing daily therapy in men with premature ejaculation (PE).
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation....
EjaculationThe primary purpose of the study is to demonstrate that dapoxetine can prolong intravaginal ejaculatory latency time (IELT) compared with placebo in men with premature ejaculation (PE).